Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study

Keyphrases

• Adverse Events 30%
• Clinical Trials 10%
• Cough 10%
• Equivalent Dose 10%
• Functional Improvement 10%
• Infant Patients 10%
• Infantile Onset 20%
• Intrathecal 10%
• Late-onset 20%
• Long-term Benefit 10%
• Motor Function 10%
• Motor Milestones 10%
• Nusinersen 100%
• Pneumonia 10%
• Pyrexia 10%
• Responder Rate 10%
• Risk-benefit 10%
• Sham 10%
• Sham Procedure 20%
• Significant Level 10%
• Small Sample Size 10%
• Spinal muscular Atrophy 100%
• Treatment Effect 10%
• Trial Duration 10%
• Upper Respiratory Tract Infection 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 30%
• Clinical Trial 10%
• Coughing 10%
• Fever 10%
• Intrathecal 10%
• Nusinersen 100%
• Spinal Muscular Atrophy 100%
• Upper Respiratory Tract Infection 10%